Replies to post #293178 on Amarin Corp Plc (AMRN)

[HinduKush]

Rose,

Generic V makers infringing into the R-I population but realistically it has often been said that most scripts for these omega products has been off label. I know there is a technical difference but Lovaza (and gen L) is basically doing the same thing right now - cutting into V’s R-I population. Now if my memory is right, Lovaza was selling to that pop before V.

Much interested to know who these Lovaza prescribers are? Are they prescribers who:
(1) Are treating an elevated TG population that has no low cost Vascepa coverage to speak of (ie Medicaid patients)
(2) Do not yet understand the differences bewteen EPA DHA and the benefits of R-IT?
(3) Do the same thing for TG elevations that they have done for years (out of habit, indolence, ignorance, take your pick) and wish to keep doing it irrespective of scientific evidence...in which case they cannot be brought into the Vascepa fold.
Apart from cost advantage in the right population (poorly insured/uninsured) I am struggling to see why generic Lovaza persists at the levels of prescription it still enjoys (albeit diminishing).
As for using Lovaza to treat R-IT type patients--to do so is to reveal complete therapeutic ignorance, and commit involuntary malpractice -the medical equivalent of manslaughter.
HK